Denali Therapeutics Inc. (DNLI) Tops Q4 EPS by 2c

Denali Therapeutics Inc. (NASDAQ: DNLI) reported Q4 EPS of ($0.73), $0.02 better than the analyst estimate of ($0.75).

For earnings history and earnings-related data on Denali Therapeutics Inc. (DNLI) click here.

You May Also Be Interested In

• Key things to know ahead of SK Hynix’s blockbuster US listing
• Applied Materials surges as CEO signals multi-year chip boom
• Sandisk (SNDK) call put ratio 1.5 calls to 1 put as share price up 7.6%